These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 24423851)

  • 61. Stereotactic ablative body radiotherapy boost for cervical cancer when brachytherapy boost is not feasible.
    Lee TH; Song C; Kim IA; Kim JS; Kim YB; Kim K; No JH; Suh DH; Chung JB; Eom KY
    Radiat Oncol; 2021 Aug; 16(1):148. PubMed ID: 34384450
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Feasibility of dose escalation using intensity-modulated radiotherapy in posthysterectomy cervical carcinoma.
    D'Souza WD; Ahamad AA; Iyer RB; Salehpour MR; Jhingran A; Eifel PJ
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1062-70. PubMed ID: 15752885
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Combined intensity-modulated radiation therapy and brachytherapy in the treatment of cervical cancer.
    Macdonald DM; Lin LL; Biehl K; Mutic S; Nantz R; Grigsby PW
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):618-24. PubMed ID: 18407429
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Feasibility of shrinking field radiation therapy through 18F-FDG PET/CT after 40 Gy for stage III non-small cell lung cancers.
    Ding XP; Zhang J; Li BS; Li HS; Wang ZT; Yi Y; Sun HF; Wang DQ
    Asian Pac J Cancer Prev; 2012; 13(1):319-23. PubMed ID: 22502693
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Definitive salvage for vaginal recurrence of endometrial cancer: the impact of modern intensity-modulated-radiotherapy with image-based HDR brachytherapy and the interplay of the PORTEC 1 risk stratification.
    Vargo JA; Kim H; Houser CJ; Berhane H; Sukumvanich P; Olawaiye AB; Kelley JL; Edwards RP; Comerci JT; Huang M; Courtney-Brooks M; Beriwal S
    Radiother Oncol; 2014 Oct; 113(1):126-31. PubMed ID: 25241996
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes.
    Würschmidt F; Petersen C; Wahl A; Dahle J; Kretschmer M
    Radiat Oncol; 2011 May; 6():44. PubMed ID: 21529377
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Technical details and clinical outcomes after high-dose-rate intracavitary brachytherapy for squamous cell carcinoma of external auditory canal and external beam radiotherapy for nodal coverage: A case report.
    Dumago MP; Yu KKL; Jacomina LE; Yap ET; Jainar CJE; Bojador MR; Fernando AF; Bacorro WR; Mejia MA
    J Contemp Brachytherapy; 2023 Feb; 15(1):75-80. PubMed ID: 36970441
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Randomised Phase II Feasibility Trial of Image-guided External Beam Radiotherapy With or Without High Dose Rate Brachytherapy Boost in Men with Intermediate-risk Prostate Cancer (CCTG PR15/ NCT01982786).
    Vigneault E; Morton G; Parulekar WR; Niazi TM; Springer CW; Barkati M; Chung P; Koll W; Kamran A; Monreal M; Ding K; Loblaw A
    Clin Oncol (R Coll Radiol); 2018 Sep; 30(9):527-533. PubMed ID: 29903505
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Impact of different treatment plans on EQD
    Gul OV; Inan G; Basaran H
    J Egypt Natl Canc Inst; 2021 Oct; 33(1):28. PubMed ID: 34604928
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California-San Francisco experience.
    Sultanem K; Shu HK; Xia P; Akazawa C; Quivey JM; Verhey LJ; Fu KK
    Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):711-22. PubMed ID: 11020568
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A planning study of radiotherapy dose escalation of PET-active tumour volumes in non-small cell lung cancer patients.
    Møller DS; Khalil AA; Knap MM; Muren LP; Hoffmann L
    Acta Oncol; 2011 Aug; 50(6):883-8. PubMed ID: 21767188
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Influence of organ motion on conformal vs. intensity-modulated pelvic radiotherapy for prostate cancer.
    Hysing LB; Skorpen TN; Alber M; Fjellsbø LB; Helle SI; Muren LP
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1496-503. PubMed ID: 18538493
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Image-based multichannel vaginal cylinder brachytherapy for vaginal cancer.
    Vargo JA; Kim H; Houser CJ; Sukumvanich P; Olawaiye AB; Kelley JL; Edwards RP; Comerci JT; Huang M; Courtney-Brooks M; Beriwal S
    Brachytherapy; 2015; 14(1):9-15. PubMed ID: 25456026
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Intensity modulated proton beam radiation for brachytherapy in patients with cervical carcinoma.
    Clivio A; Kluge A; Cozzi L; Köhler C; Neumann O; Vanetti E; Wlodarczyk W; Marnitz S
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):897-903. PubMed ID: 24119834
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Application value of reduced field intensity modulated radiation therapy for advanced cervical cancer].
    DU XL; Sheng XG; Wang C; Yu H; Song QQ; Pan CX
    Zhonghua Zhong Liu Za Zhi; 2013 Dec; 35(12):925-31. PubMed ID: 24506963
    [TBL] [Abstract][Full Text] [Related]  

  • 76. CT based 3-dimensional treatment planning of intracavitary brachytherapy for cancer of the cervix: comparison between dose-volume histograms and ICRU point doses to the rectum and bladder.
    Hashim N; Jamalludin Z; Ung NM; Ho GF; Malik RA; Phua VC
    Asian Pac J Cancer Prev; 2014; 15(13):5259-64. PubMed ID: 25040985
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Normal tissue dosimetric comparison between HDR prostate implant boost and conformal external beam radiotherapy boost: potential for dose escalation.
    Hsu IC; Pickett B; Shinohara K; Krieg R; Roach M; Phillips T
    Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):851-8. PubMed ID: 10705005
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Conventional high-dose-rate brachytherapy with concomitant complementary IMRT boost: a novel approach for improving cervical tumor dose coverage.
    Duan J; Kim RY; Elassal S; Lin HY; Shen S
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):765-71. PubMed ID: 18164832
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Point vs. volumetric bladder and rectal doses in combined intracavitary-interstitial high-dose-rate brachytherapy: correlation and comparison with published Vienna applicator data.
    Yaparpalvi R; Mutyala S; Gorla GR; Butler J; Mah D; Garg MK; Kalnicki S
    Brachytherapy; 2008; 7(4):336-42. PubMed ID: 18782683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.